Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro. The FDA has approved ...

It remains in phase 3 as a once-daily oral regimen given alongside the company's non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine), which was approved by the FDA in 2019.